Monday morning my email inbox lit up. A Wall Street Journal article–both online and in the hard copy edition–about the FDA’s unprecedented approval of three anti-myeloma drugs in less than a month was featured front and center.
I kicked off my 2016 posts yesterday this way: “Euphoria over a myeloma free PET scan doesn’t make everything else OK. I’ve been struggling with post transplant side effects… Still plenty of drama to kick off 2016.”
Euphoria over a myeloma free PET scan doesn’t make everything else OK. I’ve been struggling with post transplant side effects. Like many of you, bumps in the medical insurance road have bubbled up unexpectedly. Still plenty of drama to kick off 2016.
New checkpoint inhibitor studies combining the experimental drug, Keytruda, with Revlimid, are working in patients who have become refractory to Revlimid.
Never a dull moment. Our end of Amelia Island lost power over the holiday. It happens a lot. Even when it isn’t windy, a heavy rain can leave us without power. The unusual part this time: our electricity was off for so long. It usually sputters back on after an hour or two.
It’s hard to believe that we’re only three months away from the 3rd Annual Pat’s Myeloma Beach Party. The event is a “party” in name only; there will be 15 myeloma experts on hand to address topics that last year’s attendees and readers feel are most important to them.
Did you see the MMRF’s outline of important myeloma related news at ASH this year? Short and to the point.
Saturday I shared a link to an interview Jenny Ahlstrom did with me the second day at ASH. Can’t get enough of me unabashedly sharing my opinions about myeloma therapy options on video? Then fasten your seatbelts! CLL survivor and dear friend, Carol Preston, interviewed me at ASH for Patient Power.
Good friend and fellow myeloma survivor, Jenny Ahlstrom, is a lot better at the technical side of blogging than I am. She uses a lot of video on her site. Jenny interviewed me on Sunday at ASH. You can listen to it here:
Sometimes Christmas day can be a letdown. Let’s face it; the media and retailers build it up so much it’s hard to live the idealized version. Am I right? That said, the time I spent today with Pattie, our Island Dog and Calypso Kitties was amazing. I didn’t even think about checking email or posting […]
I understand that all of my reader’s don’t celebrate Christmas. After all, myeloma doesn’t respect religious or political boundries; it’s an equal opportunity dose of misery. Even so, I thought that Christmas Eve might be the perfect time to catch up on how some of our friends we’ve been following this past year are doing.
My good friend from north of the border, Nancy Shamanna, asked me to share this link to a survey for patients that have taken daratumumab (Darzalex). She’s hoping a positive response might move Canadian officials to adopt the new immunotherapy sooner rather than later:
Another exciting, new immunotherapy may be on the horizon: Keytruda
Thursday I ran an emotional post about being “myeloma free.” Everyone understands that’s only an expression, right? Few myeloma patients/survivors are ever truly cancer free.
ASH, unscheduled trips to the ICU, Iowa City drama. A lot has happened since I ran the last installment of Danny Parker’s series about blood glucose and metformin.
This is awesome news; another source of financial assistance for myeloma patients in need.
I promised to follow up on yesterday’s amazing news. Dr. Tricot reassures me that my tests confirm there isn’t any active myeloma left.
Looks like our highly toxic gamble to try a pair of salvage autologous stem cell transplants worked! I’m at the airport getting ready to board a plane to Atlanta on the way home, so no time to post details…
Last week I had the opportunity to interview the Senior Director of Clinical Research for Janssen Pharmaceuticals, Dr. Tahamtan Ahmadi, PhD. Janssen is the company that manufacturers newly FDA approved Darzalex (daratumumab). I promised a more detailed follow up and I’m glad to follow through.
I unceremoniously experienced my first case of C. diff during the first of my two, modified autologous stem cell transplants this summer. All I knew is everyone wore yellow paper gowns when they came in and out of my room–and I needed to pull an IV pole with me as I sprinted the six steps […]